10 research outputs found
Pulsed low-dose chemotherapy schedule suppresses circulating angiogenic factor bFGF during thoracic radiotherapy
Concurrent chemoradiation for locally advanced cancer of the oral tongue and base of tongue
A phase II study of induction docetaxel/cisplatin with rhG-CSF and concurrent pulsed docetaxel chemoradiation for stage III non-small cell lung cancer (NSCLC)
Recommended from our members
Pulsed paclitaxel radiosensitization for thoracic malignancy: A therapeutic approach based on preclinical research of human lung cancer cells
Recommended from our members
Low dose pulsed paclitaxel and concurrent radiation for thoracic malignancies: A phase I/II clinical trial based on cell cycle studies of human lung cancer cells
Stereotactic radiosurgery for glioblastoma: retrospective analysis
Abstract Purpose This retrospective study was done to better understand the conditions for which stereotactic radiosurgery (SRS) for glioblastoma may be efficacious. Methods Between 2000 and 2007, 33 patients with a pathological diagnosis of glioblastoma received SRS with the Novalis® Shaped Beam Radiosurgery system. Eighteen patients (54%) underwent salvage SRS for recurrence while 15 (45%) patients received upfront SRS following standard fractionated RT for newly diagnosed glioblastoma. Results There were no RTOG grade >2 acute side effects. The median survival after SRS was 6.7 months (range 1.4 – 74.7). There was no significant difference in overall survival (from the time of initial diagnosis) with respect to the timing of SRS (p = 0.2). There was significantly better progression free survival in patients treated with SRS as consolidation versus at the time of recurrence (p = 0.04). The majority of patients failed within or at the margin of the SRS treatment volume (21/26 evaluable for recurrence). Conclusion SRS is well tolerated in the treatment of glioblastoma. As there was no difference in survival whether SRS is delivered upfront or at recurrence, the treatment for each patient should be individualized. Future studies are needed to identify patients most likely to respond to SRS.</p